Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCHW) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Envoy Medical (COCHW) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Envoy Medical's Cash from Financing Activities fell 5604.19% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 2348.59%. This contributed to the annual value of $20.2 million for FY2024, which is 509.35% down from last year.
  • As of Q3 2025, Envoy Medical's Cash from Financing Activities stood at $2.6 million, which was down 5604.19% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Envoy Medical's Cash from Financing Activities registered a high of $15.7 million during Q3 2023, and its lowest value of -$1.5 million during Q4 2023.
  • For the 4-year period, Envoy Medical's Cash from Financing Activities averaged around $4.0 million, with its median value being $3.6 million (2025).
  • In the last 5 years, Envoy Medical's Cash from Financing Activities crashed by 17270.0% in 2023 and then surged by 48631.36% in 2024.
  • Quarter analysis of 4 years shows Envoy Medical's Cash from Financing Activities stood at $2.0 million in 2022, then crashed by 172.7% to -$1.5 million in 2023, then surged by 486.31% to $5.6 million in 2024, then crashed by 53.69% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $4.4 million for Q2 2025, and $3.6 million during Q1 2025.